EMA Lapsed: Paglitaz (pioglitazone hydrochloride) — Krka, d.d., Novo mesto

View source ↗

Summary

The EMA indicates that Paglitaz (pioglitazone hydrochloride) by Krka has lapsed, with Type 2 diabetes mellitus as the therapeutic area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Paglitaz (pioglitazone hydrochloride)

Snippet

Status: Lapsed. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Krka, d.d., Novo mesto. Decision date: 15/01/2014